Clinical trial
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
NCT03825731 is registered in ClinicalTrials.gov with Hebei Yanda Ludaopei Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
- Lead sponsor
- Hebei Yanda Ludaopei Hospital
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- January 17, 2019
- Completion date
- September 16, 2019
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
b-cell acute lymphoblastic leukemia